MX2014004025A - Metodos de valoracion de riesgo de lmp y aparatos relacionados. - Google Patents

Metodos de valoracion de riesgo de lmp y aparatos relacionados.

Info

Publication number
MX2014004025A
MX2014004025A MX2014004025A MX2014004025A MX2014004025A MX 2014004025 A MX2014004025 A MX 2014004025A MX 2014004025 A MX2014004025 A MX 2014004025A MX 2014004025 A MX2014004025 A MX 2014004025A MX 2014004025 A MX2014004025 A MX 2014004025A
Authority
MX
Mexico
Prior art keywords
pml
methods
subject
risk assessment
related apparatus
Prior art date
Application number
MX2014004025A
Other languages
English (en)
Inventor
Nicholas Schwab
Tilman Schneider-Honendorf
Heinz Wiendl
Original Assignee
Univ Muenster Wilhelms
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenster Wilhelms filed Critical Univ Muenster Wilhelms
Publication of MX2014004025A publication Critical patent/MX2014004025A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invención proporciona un método para valorar el riesgo de ocurrencia de leucoencefalopatía multifocal progresiva (LMP) en un sujeto, así como un método para estratificar un sujeto que se somete al tratamiento con el agente de bloqueo VLA-4 para la suspensión del tratamiento con el agente de bloqueo VLA-4. Estos métodos comprenden detectar el nivel de células T que expresan L-selectina (CD62L) y opcionalmente LFA-1 en una muestra del sujeto.
MX2014004025A 2011-10-17 2012-10-16 Metodos de valoracion de riesgo de lmp y aparatos relacionados. MX2014004025A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11185439 2011-10-17
EP12158369 2012-03-07
PCT/EP2012/070465 WO2013057092A1 (en) 2011-10-17 2012-10-16 Methods of risk assessment of pml and related apparatus

Publications (1)

Publication Number Publication Date
MX2014004025A true MX2014004025A (es) 2014-08-01

Family

ID=47215496

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014004025A MX2014004025A (es) 2011-10-17 2012-10-16 Metodos de valoracion de riesgo de lmp y aparatos relacionados.
MX2014004319A MX2014004319A (es) 2011-10-17 2012-10-16 Valoracion del riesgo de pml (leucoencefalopatia multifocal progresiva) y metodos basados en la misma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014004319A MX2014004319A (es) 2011-10-17 2012-10-16 Valoracion del riesgo de pml (leucoencefalopatia multifocal progresiva) y metodos basados en la misma.

Country Status (7)

Country Link
US (1) US20150105278A1 (es)
EP (2) EP2769223A1 (es)
AU (2) AU2012325017A1 (es)
BR (2) BR112014009310A2 (es)
CA (2) CA2848587A1 (es)
MX (2) MX2014004025A (es)
WO (2) WO2013057096A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038257A (zh) 2010-04-16 2013-04-10 比奥根艾迪克Ma公司 抗vla-4抗体
CA2916028A1 (en) * 2013-07-05 2015-01-08 Biogen Ma Inc. Compositions and methods for treatment of stroke
WO2015042254A1 (en) * 2013-09-18 2015-03-26 The Johns Hopkins University Bk virus serology assessment of progressive multifocal leukoencephalopathy (pml) risk
EP3110976B1 (en) * 2014-02-27 2020-05-13 Biogen MA Inc. Method of assessing risk of pml
WO2017134178A1 (en) * 2016-02-05 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Imaging method for predicting the onset of multiple sclerosis
WO2018140510A1 (en) * 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
WO2019236417A1 (en) 2018-06-04 2019-12-12 Biogen Ma Inc. Anti-vla-4 antibodies having reduced effector function

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5936065A (en) 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
CA2261974A1 (en) 1996-07-25 1998-02-05 Biogen, Inc. Molecular model for vla-4 inhibitors
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
ES2206953T3 (es) 1997-06-23 2004-05-16 Tanabe Seiyaku Co., Ltd. Inhibidores de la adherencia celular mediada por alfa 4-beta 1.
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6455550B1 (en) 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
JP3180906B2 (ja) 1998-11-12 2001-07-03 日本電気株式会社 磁気抵抗効果型複合ヘッドの製造方法
ES2228458T3 (es) 1999-02-18 2005-04-16 F. Hoffmann-La Roche Ag Derivados de tioamida.
US6265572B1 (en) 1999-04-20 2001-07-24 Hoffmann-La Roche Inc. Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US6365619B1 (en) 1999-07-22 2002-04-02 Novartis Ag Treatment of arteriosclerosis
WO2001036376A1 (fr) 1999-11-18 2001-05-25 Ajinomoto Co., Inc. Nouveaux dérivés de la phénylalanine
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
EP1244656A1 (en) 1999-12-28 2002-10-02 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2001070670A1 (fr) 2000-03-23 2001-09-27 Ajinomoto Co., Inc. Nouveau derive de phenylalanine
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
WO2002008206A1 (en) 2000-07-21 2002-01-31 Elan Pharmaceuticals, Inc. 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
US7015216B2 (en) 2000-07-21 2006-03-21 Elan Pharmaceuticals, Inc. Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors
KR100675036B1 (ko) 2000-08-18 2007-01-29 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체 및 이를 포함하는 의약품
PL364142A1 (en) 2001-02-22 2004-12-13 Celltech R & D Limited Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors
WO2002074789A2 (en) * 2001-03-20 2002-09-26 Baylor College Of Medicine Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
JP4164871B2 (ja) 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
JP4452899B2 (ja) 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
GB0216568D0 (en) 2002-07-17 2002-08-28 Celltech R&D Ltd Chemical compounds
GB0216571D0 (en) 2002-07-17 2002-08-28 Celltech R&D Ltd Chemical compounds
US7446125B2 (en) 2003-04-09 2008-11-04 Universidad Del Pais Vasco Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders
US7527954B2 (en) 2003-10-01 2009-05-05 Eth Zurich Method for in vitro evolution of polypeptides
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
ES2387317T3 (es) 2005-03-03 2012-09-20 Seedlings Life Science Ventures, Llc. Procedimiento de control de riesgos de pacientes en tratamiento con natalizumab
JP2009528359A (ja) 2006-02-28 2009-08-06 エラン ファーマシューティカルズ，インコーポレイテッド ナタリズマブを用いて炎症性疾患および自己免疫性疾患を治療する方法
WO2008097190A1 (en) 2007-02-05 2008-08-14 Agency For Science, Technology And Research Methods of electrically detecting a nucleic acid by means of an electrode pair
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
US20100285601A1 (en) 2007-09-28 2010-11-11 Agency For Science, Technology And Research Method of electrically detecting a nucleic acid molecule
US8415150B2 (en) * 2009-02-24 2013-04-09 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (PML)
EP2226392A1 (en) * 2009-03-03 2010-09-08 Assistance Publique - Hôpitaux de Paris Method for detecting JCV infection
RU2603097C2 (ru) 2010-12-21 2016-11-20 Селексис Фармасьютикалс Корпорейшн Антитела к р-селектину и способы их применения и идентификации

Also Published As

Publication number Publication date
MX2014004319A (es) 2015-05-15
AU2012325013A1 (en) 2014-03-27
EP2769222A1 (en) 2014-08-27
US20150105278A1 (en) 2015-04-16
CA2850885A1 (en) 2013-04-25
AU2012325017A1 (en) 2014-04-17
WO2013057096A1 (en) 2013-04-25
BR112014009144A2 (pt) 2017-06-13
CA2848587A1 (en) 2013-04-25
BR112014009144A8 (pt) 2017-06-20
WO2013057092A1 (en) 2013-04-25
EP2769223A1 (en) 2014-08-27
BR112014009310A2 (pt) 2017-04-11

Similar Documents

Publication Publication Date Title
MX2014004025A (es) Metodos de valoracion de riesgo de lmp y aparatos relacionados.
PL3671239T3 (pl) Urządzenie i sposób diagnozowania stycznika elektrody dodatniej pakietu akumulatorowego
ZA201103152B (en) Modified apparatus and method for assessment,evaluation,evaluation and grading of gemstones
HUE064183T2 (hu) Elõre feltöltött teszt szubsztrát LAL-reaktív vegyületek tesztelésére, eljárás azok alkalmazására és eljárás azok elõállítására
CY1121981T1 (el) Μεθοδος για τον προσδιορισμο κινδυνου pml
EP2669696A4 (en) METHOD AND DEVICE FOR PREDICTING THE PERFORMANCE OF A BATTERY AND BATTERY MANAGEMENT SYSTEM THEREWITH
EP2995676A4 (en) DEVICE FOR ANALYZING CELLS AND FOR MONITORING CELL CULTURE AND METHOD FOR ANALYZING CELLS AND MONITORING CELL CULTURE USING THE SAME
SG11201406192VA (en) Method for assessing the treatment of attention-deficit/hyperactivity disorder
WO2014022826A3 (en) Biomarker associated with risk of melanoma reoccurrence
EP2834615A4 (en) MOBILE TESTING SYSTEM AND METHODS FOR IN SITU CHARACTERIZATION OF DEPENDENT RIGIDITY DETAILED TO CONSTRAINTS AND DEFLICTION AND PORTABLE CAPACITY OF SOILS AND GEO-MATERIALS
ZA201206955B (en) Process for the recovery of gold from an ore in chloride medium with a nitrogen species
EP2952866A4 (en) METHOD FOR EVALUATING RESIDUAL SOLICITATION USING INSTRUMENTATED PENETRATION HARDNESS TESTING TECHNIQUE, STORAGE MEDIUM MEMORY COMPRISING COMPUTER PROGRAMMING, AND PENETRATION HARDNESS TEST APPARATUS FOR REALIZING HARDNESS TESTING BY INSTRUMENTED PENETRATION BY OPERATING THE STORAGE MEDIUM
GB2490913B (en) Electrochemical cell and method for operation of the same
IL285288A (en) Cell concentration methods and devices for use in automatic urictors
GB201209721D0 (en) Methods and apparatus for on-line analysis of financial accounting data
MX357429B (es) Predictores para el tratamiento del cáncer.
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
SG10201707999RA (en) Electrodes/electrolyte assembly, reactor and method for direct amination of hydrocarbons
EP2872676A4 (en) APPARATUS, METHOD AND SYSTEM FOR RAPID COMMISSIONING, REMOVAL AND REPLACEMENT OF AN ELECTROLYTIC CELL
ZA201500458B (en) Method for recovering pulping chemicals and reducing the concentration of potassium and chloride therein
WO2013077814A3 (en) Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy
PT3046459T (pt) Sistema e método para avaliação de acomodação residual em olhos presbiópicos
PL2434570T3 (pl) Bateria elektrochemiczna i sposób usuwania ogniw z tego rodzaju baterii
HUE062071T2 (hu) Eljárás elektrokémiai cellák regenerálására
EP2916138A4 (en) BATTERY PACKING SYSTEM AND METHOD FOR TESTING SUCH A BATTERY PACK